
2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "MIST5 Trial - Niraparib & Dostarlimab in Platinum-Sensitive Relapsed Mesothelioma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Dean Fennell
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Dean Fennell
111 views
June 6, 2024
Chapters
MIST5 Trial Results & Conclusions
00:00
Study Design & Patient Characteristics
01:16
Efficacy, Safety & Correlative Research
04:35
Comments 0
Login to view comments.
Click here to Login
Lung